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Previewsto remarkable advances in disease
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Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual
disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function
mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal
hematopoietic cells through increased stress resistance.The myelodysplastic syndromes (MDSs)
are a heterogeneous group of clonal
bone marrow malignancies characterized
by ineffective hematopoiesis, the pres-
ence of dysplastic cells in the bone
marrow, and peripheral blood cytopenias.
MDS occurs more frequently in older
males and in individuals with prior expo-
sure to cytotoxic therapy (Garcia-Manero,
2012), and individuals with MDS have an
increased risk of developing acute
myeloid leukemia (AML) (Heaney and
Golde, 1999). Recent experimental evi-
dence suggests that MDS arises from
a series of transforming events that
accumulate to generate pre-leukemic
stem cells (pre-LSCs), the precursors of
fully transformed LSCs (Pandolfi et al.,
2013). Transformational genetic and
epigenetic changes are believed to selec-
tively expand pre-LSCs in the bonemarrow, which then out-compete normal
hematopoietic stem and progenitor cells
(HSPCs). Genome-wide studies have
recently identified a number of genetic
lesions that are implicated in this process
and the development and/or progression
of MDS. These lesions have so far been
found in splicing factor genes (e.g.,
SF3B1 and SRSF2) as well as genes
involved in regulating DNA methylation
(e.g., TET2, IDH, and DNMT3A), histone
modification (e.g., ASXL1 and EZH2),
and several signal transduction and
transcription factors (e.g., RUNX1, p53,
EVI1, JAK2, and FLT3). In this issue
of Cell Stem Cell, Cai et al. (2015)
show that mutations in the transcription
factor RUNX1 reduce ribosomal biogen-
esis and provide a competitive advan-
tage to pre-LSCs by enhancing stress
resistance.Almost half of MDS patients present
with recurring karyotypic abnormalities
affecting chromosomes 5, 7, 8, and 20,
many of which impact the ribosome.
Hemizygous loss of the ribosomal
protein gene Rps14 contributes to the
development of anemia in 5q syndrome
(Ebert et al., 2008). Nucleophosmin,
which is located on chromosome
5q35.1, has been implicated in MDS
pathogenesis and is also critical for ribo-
some function (Grisendi et al., 2006;
Reschke et al., 2013). Other genetic
abnormalities cause impaired ribosome
biogenesis (Ribi) and function—a collec-
tion of disorders known as ribosomopa-
thies. Researchers have also found an
association between ribosomal stress
and activation of p53. In their current
study, Cai et al. have focused on
Runx1, a DNA binding transcription7, August 6, 2015 ª2015 Elsevier Inc. 129
Figure 1. Hypothetical Development of Therapeutic Strategies Targeting Stress-Resistant
pre-LSCs and/or LSCs
Loss of function of RUNX1 mutations in HSPCs can be early or later events in the progression of MDS
or AML, and these mutations can provide pre-LSCs with selective advantages over normal HSCs.
Determining the precise mechanisms of survival and stress resistance in these cells may lead to the devel-
opment of combination therapies to eradicate leukemic cells.
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Previewsfactor that is found mutated in MDS
and AML, particularly in patients with
previous exposure to genotoxic agents.
In the mouse, loss-of-function mutations
of Runx1 cause defects in lymphocyte
and megakaryocytic development (Cai
et al., 2011). Intriguingly, deficiency of
Runx1 alone only minimally impacts
long-term hematopoietic stem cells (LT-
HSCs) (Cai et al., 2011), while Runx1;
Runx3 double-knockout mice exhibit
lethal phenotypes due to bone marrow
failure and myeloproliferative disorder
(Wang et al., 2014). Early events such
as RUNX1 mutations are known to
generate pre-LSCs. However, the molec-
ular mechanisms underlying the com-
petitive expansion of pre-LSCs through
loss-of-function RUNX1 mutation have
yet to be fully understood.
Cai and colleagues now elucidate some
of the precise machinery involved in
this process. Using conditional Runx1-
deficient mice, they first found that
Runx1 deficiency protects HSPCs from
various stresses. Runx1-ablated HSPCs
expanded in the bone marrow relative to
competitor cells, when donor cells were
subjected to a low level of irradiation
prior to transplantation. Less apoptosis
was observed in Runx1D/D HSPCs after
Ara-C treatment and endoplasmic reticu-
lum (ER) stress induced by tunicamycin.130 Cell Stem Cell 17, August 6, 2015 ª2015Based on these data, Cai et al. concluded
that Runx1-deficient HSPCs are resistant
to both genotoxic and endogenous
stresses. Runx1-deficient HSPCs are
slow cycling and have a low metabolic
profile, small cell phenotype, and
decreased biosynthetic capacity with a
balanced reduction in Ribi. To understand
the mechanisms underlying decreased
Ribi, they analyzed ChIP-seq data
generated in human CD34+ HSPCs and
found that RUNX1 binding is highly en-
riched at the promoters of Ribi genes. In
murine Runx1D/D HSPCs, expression
levels of ribosome genes occupied by
RUNX1 were reduced. Acute deletion of
Runx1 in vitro decreases 45S rRNA and
the translational rate in HSPCs. These
data suggest that RUNX1 directly regu-
lates Ribi through its enriched binding
at the promoters of Ribi genes, including
the genes encoding structural com-
ponents of the ribosome. Interestingly,
Runx1-deficient HSPCs have lower levels
of p53 protein and reduced apoptosis.
Increased levels of p53 or its target genes
by radiation were also attenuated in
Runx1D/D HSPCs. Activation of p53
alone fails to reverse the low apoptotic
phenotype in Runx1-deleted HSPCs,
and increased mTOR signaling partially
restores Ribi, but not their reduced
apoptotic phenotype.Elsevier Inc.While these findings represent a step
forward in developing a coherent picture
of the competition between pre-LSCs
and HSPCs and how this may lead
to full-blown malignancies, many gaps
remain in this developing story. Perhaps
Cai et al.’s most compelling new findings
are the links demonstrated between
Runx1 mutations, reduced Ribi, and
p53-independent stress resistance phe-
notypes. These findings, however, raise
a series of theoretical issues. One such
question is the mechanism of how the
changes in Ribi induced by Runx1 muta-
tions lead to stress resistance in HSPCs.
In other words, is this phenomenon simply
the result of slow growth resulting from
Runx1 deficiency, or do other mecha-
nisms contribute specifically in the case
of reduced Ribi? It will also be interesting
to explore which ribosome genes are
major players in Ribi phenotypes induced
by Runx1 mutations.
For example, are one or a fewmembers
of the perturbed ribosome genes able to
restore the phenotype of Runx1-mutated
HSPCs? Located on chromosomal 21,
the RUNX1 gene is also involved in chro-
mosomal translocations in leukemia, and
the RUNX1-ETO fusion protein by t(8;21)
is one of the most common translocations
in AML (Lam and Zhang, 2012). It will also
be interesting to unravel whether Ribi
contributes to leukemia pathogenesis
induced by RUNX1 fusion proteins. The
answer to these questions will no doubt
be the focus of future studies, which
will lead to a deeper characterization
of these mechanisms, such as specific
downstream targets, and the develop-
ment of new therapeutic approaches
designed to eradicate stress-resistant
leukemic and pre-leukemic HSPCs while
restoring normal hematopoiesis (Figure 1).
As ribosomopathies have also been asso-
ciated with an increased predisposition to
cancer, these findings may have wide-
ranging implications in other cancers.REFERENCES
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Stem cell self-renewal is intrinsically associated with cell cycle control. However, the precise mechanisms
coordinating cell fate choices and cell cycle remain to be fully uncovered. Now in Cell, Gonzales et al.
(2015) and colleagues demonstrate that factors controlling the G2/M phase are necessary to block pluripo-
tency upon induction of differentiation.Stem cells are defined by their ability to
proliferate almost indefinitely while main-
taining their capacity to differentiate into
several cell types. The coordination of
these two properties, self-renewal and
multipotency, is essential to ensure
proper embryonic development, organo-
genesis, organ homeostasis, and tissue
repair upon injury. Furthermore, uncon-
trolled proliferation of stem cells could
play a major role in diseases such as can-
cer. Thus, understanding the interplay
between cell-cycle regulation and cell
fate decisions represents a major interest
for the stem cell field. Nonetheless, the
study of these mechanisms has been
restricted by the technical difficulties
impairing investigations of cell-cycle reg-
ulations in vivo and also by the lack of
appropriate in vitro model systems. Now
in Cell, Huck-Hui Ng and colleagues
demonstrate that pluripotency of human
embryonic stem cells (hESCs) is con-
trolled by factors necessary for the
transition of the G2/M phase of the cell
cycle. This study provides new insights
into the mechanisms by which stem cells
exploit cell-cycle machinery to control
their cell fate decisions (Gonzales et al.,
2015).The cell cycle can be divided into four
different phases: the G1 phase, during
which a cell decides to engage in a new
division; the S phase, when DNA is repli-
cated; the G2 phase, which allows DNA
repair mechanisms; and the M phase, at
the end of which cells divide. The G1
phase has been the focus of a broad num-
ber of studies on stem cells since cell fate
choices seems to occur or at least be initi-
ated during this part of the cell cycle.
Indeed, several reports have shown that
stem cells can perceive differentiation sig-
nals specifically in G1. Of particular inter-
est, the early G1 phase is permissive
for endoderm differentiation in hESCs
while the late G1 phase is only permis-
sive for neuroectoderm specification
(Pauklin and Vallier, 2013). This divergent
capacity of differentiation is established
by CyclinD/CDK4-6, which are expressed
during the late G1 phase. These cell-cycle
regulators inhibit the Activin/Nodal sig-
naling pathway, which is known to block
neuroectoderm differentiation of hESCs
while being necessary for endoderm dif-
ferentiation. Importantly, the importance
of the G1 phase and CyclinD/CDK4-6
appear to be conserved in adult stem cells
(Lange et al., 2009; Mende et al., 2015).Thus, the cell-cycle machinery could
directly orchestrate initiation of differenti-
ation during the G1 phase progression in
a diversity of cell types.
The importance of S/G2 in stem cell
control is by far less explored. Regulators
of these phases of cell cycle such as
Cyclin B1 are necessary for cell survival
and their absence often results in cell
death and/or major genomic anomalies.
For these reasons, the importance of
the G2 phase in stem cell self-renewal
and differentiation remains to be fully un-
covered. The report by Gonzales et al.
(2015) remedies this shortfall by revealing
that the G2 transition could also have a
key function in the mechanisms directing
hESC differentiation.
The authors first performed an siRNA
screen to identify factors that could delay
differentiation induced by the absence or
inhibition of TGFb/Activin/Nodal and FGF
signaling, both of which are known to
be essential for the pluripotent state of
hESCs (Thomson et al., 1998; Vallier
et al., 2004). This screen revealed that
several epigenetic mechanisms such as
histone acetylation and chromatin remod-
eling are essential for the transition be-
tween pluripotency and differentiation to7, August 6, 2015 ª2015 Elsevier Inc. 131
